SCHEMBL10154347

SCHEMBL10154347

CNS(=O)(=O)c1ccc(F)c(OC)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.64
ALDH1A1 P00352 7/20 0.62
HTT P42858 4/20 0.61
SMN1; SMN2 Q16637 2/20 0.61
GAA P10253 1/20 0.61
HPGD P15428 1/20 0.61
KDM4E B2RXH2 1/20 0.59
KMT2A Q03164 4/20 0.57
MEN1 O00255 2/20 0.52
PKM P14618 1/20 0.52
TSHR P16473 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52
MAPT P10636 1/20 0.49
THRB P10828 1/20 0.49
CA12 O43570 2/20 0.47
CA9 Q16790 2/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CA3 P07451 1/20 0.47
CA4 P22748 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4608475 0.84 LMNA (0.67) LMNAALDH1A1HTTSMN1; SMN2KMT2A
Hydrochloric Acid SCHEMBL4609744 0.82 LMNA (0.65) LMNAALDH1A1HTTSMN1; SMN2KMT2A
SCHEMBL24429355 0.82 SMN1; SMN2 (0.60) LMNAALDH1A1HTTSMN1; SMN2GAA
SCHEMBL4454747 0.82 ALDH1A1 (0.68) LMNAALDH1A1HTTSMN1; SMN2GAA
SCHEMBL13211247 0.80 SMN1; SMN2 (0.59) LMNAALDH1A1HTTSMN1; SMN2GAA
SCHEMBL425487 0.80 KMT2A (0.58) LMNAALDH1A1HTTSMN1; SMN2GAA
SCHEMBL29651875 0.79 LMNA (0.55) LMNAALDH1A1HTTSMN1; SMN2GAA
SCHEMBL27459443 0.79 PTGS2 (0.55) LMNAALDH1A1HTTSMN1; SMN2GAA
SCHEMBL1816396 0.79 LMNA (0.55) LMNAALDH1A1HTTSMN1; SMN2GAA
SCHEMBL10153812 0.77 TSHR (0.61) LMNAALDH1A1HTTSMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240209001-A1 HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS Chiesi Farmaceutici S.p. A. (IT) 2024-06-27 US disclosed
US-20240209001-A1 HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS Chiesi Farmaceutici S.p. A. (IT) 2024-06-27 US disclosed
US-20240209001-A1 HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS Chiesi Farmaceutici S.p. A. (IT) 2024-06-27 US disclosed
EP-4308244-A1 HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS Chiesi Farmaceutici S.p.A. (IT) 2024-01-24 EP disclosed
CN-117098765-A Heterocyclic derivatives as Janus kinase inhibitors 奇斯药制品公司 2023-11-21 CN disclosed
WO-2022194781-A1 HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2022-09-22 WO disclosed
US-20120165309-A1 HETERO RING DERIVATIVE ASTELLAS PHARMA INC. (JP) 2012-06-28 US disclosed
EP-2397479-A1 HETERO RING DERIVATIVE Astellas Pharma Inc. (JP) 2011-12-21 EP disclosed
WO-2010092962-A1 HETERO RING DERIVATIVE アステラス製薬株式会社 (JP) 2010-08-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120165309-A1 HETERO RING DERIVATIVE IL2, PIK3R2, IL2RA LMNA 4381/4885ALDH1A1 3496/4885HTT 4317/4885
US-20240209001-A1 HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS TYK2, JAK3, JAK1 LMNA 4155/4885ALDH1A1 3553/4885HTT 3332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.